Navigation Links
Scientists investigate potential markers for a response to sunitinib in patients with metastatic RCC
Date:3/18/2013

Milan, 18 March 2013 Markers such as CA9, CD31, CD34 and VEGFR1/2 in the primary tumours might serve as predictors of a good response to a sunitinib treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to a new study to be presented at the 28th Annual EAU Congress currently on-going in Milan.

"The inactivation of the von Hippel-Lindau gene (VHL) is a common event in ccRCC and finally leads to the induction of HIF1α target genes such as CA9 and VEGF," write the authors. "Besides VEGF, the VEGF and PDGF receptors also play an important role in angiogenesis that is reflected by the microvessel density (MVD).

The tyrosine kinase inhibitor (TKI) Sunitinib targets amongst others the receptors of VEGF and PDGF and is currently one of the standard treatment options for metastatic ccRCC."

According to the researchers, there is currently a lack of predictive biomarkers for a response to TKI treatment. In this study, primary tumours from ccRCC patients, who were later treated with sunitinib, were used for biomarker analyses. In the course of the study, DNA was isolated from cryo-preserved tumour tissue specimens from 20 ccRCC patients for VHL copy number and mutation analyses. Tissue microarrays were prepared from 42 paraffin-embedded malignant and corresponding non-malignant renal tissue specimens.

Immunohistochemical staining of VHL, CA9, PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, CD31 and CD34, VEGFR1, VEGFR2, VEGFR3, CD31 and CD34 was assessed by a scoring system including staining intensity and percentage of stained tumor cells as well as vessel (endothelial) staining. The objective response rate was evaluated according to the RECIST criteria after 3, 6, 9 months and last report (12-54 months) of sunitinib treatment.

Copy number loss and mutation of VHL was observed in 60% and 50%, respectively, with 40% of the cases showing both VHL changes. These VHL gene alterations were accompanied by a reduced VHL protein staining and an increased CA9 score.

After 9 months, 45% of the patients responded to sunitinib treatment. Their response was associated with low Fuhrman grade of the primary tumour (p<0.05). The vessel staining of VEGFR1/2 was elevated in patients with a response after last report.

Patients with a response after 6 months exhibited an increased MVD and CA9 staining in the primary tumour (p<0.05) and their estimated median progression free survival (12 mo vs. 8 mo; p<0,001) and median overall survival (45 mo vs. 21 mo; p<0.001) was longer than for non-responders. High CA9 and low PDGFRα; protein expression were associated with longer overall survival (p<0.01).


'/>"/>

Contact: Ivanka Moerkerken
i.moerkerken@uroweb.org
31-026-389-0680
European Association of Urology
Source:Eurekalert

Related medicine news :

1. Scientists ID Antibody That Might Boost Cancer Therapy
2. Scientists Report Clues to Flu Shots Effectiveness
3. Scientists discuss relationship between abortion and violence against women
4. A*STAR scientists discover switch critical to wound healing
5. Scientists uncover source of ovarian stem-like cells prone to give rise to ovarian cancer
6. Defective virus surprisingly plays major role in spread of disease, UCLA life scientists report
7. OHSU scientists first to grow liver stem cells in culture, demonstrate therapeutic benefit
8. Scientists Pinpoint How Deep Brain Stimulation Eases OCD
9. Scientists make older adults less forgetful in memory tests
10. Scientists unveil secrets of important natural antibiotic
11. Fungi offers new clues in asthma fight, say Cardiff scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... 12, 2016 , ... CDRH Enforcement Trends: , Back to the Future , Feb. 25, 2016 ... Winston Churchill said, “Those who don’t learn from history are doomed to repeat it.” , ... come knocking this year. But that takes time. , Take a close look at ...
(Date:2/12/2016)... ... 12, 2016 , ... Each year, the American Physical Therapy Association (APTA) offers ... the Anaheim Convention Center. Almost 10,000 physical therapists across the country are expected to ... more about their chosen field and network with their colleagues. As in years ...
(Date:2/12/2016)... ... , ... Coco Libre, the maker of coconut water beverages with a purpose, ... Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut Water, ... gifting suite, held this year at the W Hollywood Hotel, has become a pre-show ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... at Zuckerberg San Francisco General Hospital on April 5-7. The series is a ... create new habits. The workshops cover a broad range of topics, including coaching ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Every winter, ... , This winter the West Penn Burn Center, part of the Allegheny ... #1, to bring you the “Space Heaters Need Space” campaign. , ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016  NOIT™ Research LLC, a private, ... of Change" campaign to assist needy families in obtaining ... unit sold between February 10, 2016 and March 31, ... needy family. The NOIT is an auditory stimulus that ... develop language skills. Beth Shier , ...
(Date:2/11/2016)... , Feb. 11, 2016 AAIPharma ... provider of custom manufacturing and development services for ... sterile fill-finish capabilities and capacity in its ... in demand has driven several recent investments. ... it had one filling line with small-scale lyophilization. ...
(Date:2/11/2016)... PORTLAND, Ore. , Feb. 11, 2016 ... to announce the acquisition of SolutionsRx, a full-service 340B ... hospitals. Along with providing traditional contract pharmacy services, SolutionsRx ... assist clients in navigating the complex 340B regulatory environment. ... Wellpartner. --> James R. Love , CEO ...
Breaking Medicine Technology: